title: Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City.
abstract: Data on the frequency of non-motor symptoms among patients with Parkinson's disease (PD) in Mexico has not been reported.
  
  
  OBJECTIVE
  To study the prevalence of these symptoms in a sample of Mexican PD patients attending a referral neurologic center using the Non Motor Symptoms Questionnaire (NMSQuest) and the Non Motor Symtpoms Scale (NMSS).
  
  
  METHODS
  One-hundred consecutive PD patients, of all ages and disease severity were included in a cross-sectional design study. The NMSQuest and NMSS were applied during the "on" state.
  
  
  RESULTS
  Sample had a mean age of 64.5±10.9 years and disease duration of 6.6±4.8 years. Total NMSQuest median score was 10 and the mean NMSS score was 69.3±56.7. Positive answers classified by domain were as follows: gastrointestinal symptoms 30%, urinary symptoms 60%, memory/attention/apathy 39%, hallucinations/delusions 16%, depression/anxiety 55%, sexual dysfunction 30%, cardiovascular symptoms 35%, sleep disorders 40% and miscellany 27%.
  
  
  CONCLUSIONS
  The prevalence of non-motor symptoms among mexican patients with PD is similar to other countries. Mood, cognitive and perceptual symptoms seems to be more severe in our population.
authors.affiliation: Clinical Neurodegenerative Disease Research Unit, National Institute of Neurology and Neurosurgery, Mexico. mrodriguez@innn.edu.mx
authors.forename: Mayela
authors.initials: M
authors.lastname: Rodríguez-Violante
authors.forename: Amin
authors.initials: A
authors.lastname: Cervantes-Arriaga
authors.forename: Alejandra
authors.initials: A
authors.lastname: Villar-Velarde
authors.forename: Teresa
authors.initials: T
authors.lastname: Corona
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications* / Q000453:epidemiology* / Q000503:physiopathology; D011795:Surveys and Questionnaires
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa